Evaxion to announce business update and third quarter 2024 financial results on October 31
Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q3 2024 financial results announcement and business update for October 31, 2024, before Nasdaq CM opening. The company's Executive Management will host a conference call and webcast at 13:30 CET/08:30 EST on the same day. The event is free and open to the public, with advance registration required for participation. A webcast recording will be made available on the company's website after the event.
Evaxion Biotech (NASDAQ: EVAX), un'azienda TechBio in fase clinica focalizzata sullo sviluppo di vaccini alimentati da intelligenza artificiale, ha programmato l'annuncio dei risultati finanziari del Q3 2024 e un aggiornamento aziendale per il 31 ottobre 2024, prima dell'apertura del Nasdaq CM. La Direzione Esecutiva dell'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 13:30 CET/08:30 EST nello stesso giorno. L'evento è gratuito e aperto al pubblico, con registrazione anticipata richiesta per la partecipazione. Una registrazione della trasmissione sarà disponibile sul sito web dell'azienda dopo l'evento.
Evaxion Biotech (NASDAQ: EVAX), una empresa de TechBio en etapa clínica centrada en el desarrollo de vacunas impulsadas por inteligencia artificial, ha programado el anuncio de sus resultados financieros del Q3 2024 y una actualización empresarial para el 31 de octubre de 2024, antes de la apertura del Nasdaq CM. La dirección ejecutiva de la compañía llevará a cabo una conferencia telefónica y una transmisión en línea a las 13:30 CET/08:30 EST el mismo día. El evento es gratuito y está abierto al público, requiriendo registro previo para participar. Se hará disponible una grabación de la transmisión en el sitio web de la empresa después del evento.
Evaxion Biotech (NASDAQ: EVAX), 인공지능 기반 백신 개발에 주력하는 임상 단계의 TechBio 회사가 2024년 3분기 재무 실적 발표 및 사업 업데이트를 2024년 10월 31일 나스닥 CM 개장 전에 예정하고 있습니다. 회사의 경영진이 같은 날 13:30 CET/08:30 EST에 전화 회의 및 웹 캐스트를 주최할 것입니다. 이 행사는 무료로 진행되며, 참석을 위해 사전 등록이 필요합니다. 행사가 끝난 후 회사 웹사이트에 웹 캐스트 녹화가 제공될 예정입니다.
Evaxion Biotech (NASDAQ: EVAX), une entreprise TechBio en phase clinique axée sur le développement de vaccins alimentés par l'intelligence artificielle, a prévu l'annonce de ses résultats financiers du T3 2024 et une mise à jour de l'entreprise pour le 31 octobre 2024, avant l'ouverture du Nasdaq CM. La direction exécutive de l'entreprise animera une conférence téléphonique et un webinaire le même jour à 13h30 CET/08h30 EST. L'événement est gratuit et ouvert au public, une inscription préalable étant requise pour y participer. Un enregistrement du webinaire sera disponible sur le site Web de l'entreprise après l'événement.
Evaxion Biotech (NASDAQ: EVAX), ein klinisches TechBio-Unternehmen, das sich auf die Entwicklung von KI-gestützten Impfstoffen konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das 3. Quartal 2024 und ein Unternehmensupdate für den 31. Oktober 2024, vor der Eröffnung des Nasdaq CM, angesetzt. Das Management des Unternehmens wird am selben Tag um 13:30 CET/08:30 EST eine Telefonkonferenz und einen Webcast veranstalten. Die Veranstaltung ist kostenlos und für die Öffentlichkeit zugänglich, eine frühzeitige Anmeldung zur Teilnahme ist erforderlich. Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.
Evaxion’s Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Contact information
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion-biotech.com
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
When will Evaxion Biotech (EVAX) release its Q3 2024 financial results?
What time is Evaxion Biotech's (EVAX) Q3 2024 earnings call?
How can investors access Evaxion Biotech's (EVAX) Q3 2024 earnings call?
